Telephone: +61 8 9322 4455 Facsimile: +61 8 9481 5950

13 December 2013

ASX Market Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000

Dear Sir/Madam

APPENDIX 3B – PERFORMANCE RIGHTS

Please find enclosed an Appendix 3B for the issue of 1,282,043 unlisted Performance Rights as approved by shareholders at the annual general meeting of Red 5 Limited (Company) held on 28 November 2013.

Notice given under Section 708A(5) of the Corporations Act

This notice is given by the Company under Section 708A(5)(e) of the Corporations Act in relation to an issue of performance rights which are convertible into ordinary fully paid shares, which is a class of securities quoted on the Australian Securities Exchange

The performance rights were issued without disclosure to investors under Part 6D.2, in reliance of Section 708A(5) of the Corporations Act.

As at the date of this notice, the Company has complied with:

- (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
- (b) Section 674 of the Corporations Act.

There is no excluded information as at the date of this notice, for the purposes of Sections 708A(7) and (8) of the Corporations Act.

Frank Campagna

Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96. Origin: Appendix 5. Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity		
Red 5 Limited		

ABN

73 068 647 610

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- Number of ⁺securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Unlisted Performance Rights

1,282,043

Each Performance Right entitles the holder to be issued with one ordinary fully paid share, for nil cash consideration, subject to the satisfaction of the following vesting conditions:

- (a) 50% of the Performance Rights will vest on 1 February 2016, being the third anniversary from the Commencement Date;
- (b) 50% of the Performance Rights will vest on 1 February 2017, being the fourth anniversary from the Commencement Date; and
- (c) vesting of the Performance Rights will also be based on the performance of the Company's share price relative to the S&P/ASX All Ordinaries Gold Index during the three year period prior to the third anniversary or fourth anniversary as applicable. This key performance indicator will determine the percentage of Performance Rights that vest as follows:

- (i) top quartile performance: 100% (of the 50% entitlement) of the Performance Rights will vest;
- (ii) second quartile performance: 50% (of the 50% entitlement) of the Performance Rights will vest;
- (iii) median performance and below: 0% of the Performance Rights will vest.

Other terms of the Performance Rights are contained in the notice of meeting and explanatory memorandum for the annual general meeting of shareholders of the Company held on 28 November 2013.

Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No. Shares issued as a result of the vesting of the Performance Rights will rank equally with ordinary fully paid shares as from the date of allotment of the shares.

5	CCIIA	nrico	α r	concid	aration
9	13340	DITCO	OI.	consid	crauon

6 Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b-6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c Number of +securities issued without security holder approval under rule 7.1
- 6d Number of +securities issued with security holder approval under rule 7.1A

Issue to managing director as approved by	
1 1 1 1 1 1 1 1 1 1 1	c

Nil

No

shareholders at the annual general meeting of the Company held on 28 November 2013.

бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of securities issued under an exception in rule 7.2		
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.		
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	13 December 20	013
		N. 1	+a.
		Number	⁺ Class
8	Number and *class of all *securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)	759,451,008	Ordinary shares
		Number	⁺ Class
9	Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)	70,000 40,000 70,000 40,000 1,282,043	Options (30.04.14) Options (31.12.14) Options (30.04.16) Options (31.12.16) Performance Rights
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	The Company dividend policy	does not presently have a formal 7.

⁺ See chapter 19 for defined terms.

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do +security holders sell their entitlements in full through a broker?	

⁺ See chapter 19 for defined terms.

31		lo *security holders sell <i>part</i> of their entitlements the a broker and accept for the balance?	
32		lo ⁺ security holders dispose of their entitlements by sale through a broker)?	
33	+Desp	atch date	
		Quotation of securities omplete this section if you are applying for quotation of s	ecurities
34	Type of	of securities ne)	
(a)		Securities described in Part 1	
(b)		All other securities Example: restricted securities at the end of the escrowed period, p securities when restriction ends, securities issued on expiry or conversi	artly paid securities that become fully paid, employee incentive share on of convertible securities
Enti	ties t	hat have ticked box 34(a)	
Addi	tional s	ecurities forming a new class of securities	
Tick to	indicate	you are providing the information or documents	
35		If the *securities are *equity securities, the names *securities, and the number and percentage of add	•
36		If the +securities are +equity securities, a distribution out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	on schedule of the additional ⁺ securities setting
37		A copy of any trust deed for the additional *secur	ities
Entit	ies th	nat have ticked box 34(b)	
38	Numb	per of securities for which ⁺ quotation is sought	
39	Class	of +securities for which quotation is sought	

⁺ See chapter 19 for defined terms.

40	Do the ⁺ securities rank equally in all respects from the date of allotment with an existing ⁺ class of quoted ⁺ securities?			
	If the additional securities do not rank equally, please state:			
	 the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment 			
	 the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 			
41	Reason for request for quotation now			
	Example: In the case of restricted securities, end of restriction period			
	(if issued upon conversion of another security, clearly identify that other security)			
		Number	+Class	
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 38)	Tumor	Class	
			· · · · · · · · · · · · · · · · · · ·	

Quotation agreement

- 1. *Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.
- 2. We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- 3. We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

⁺ See chapter 19 for defined terms.

4. We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Frank Campagna Date: 13 December 2013

(Director/Company secretary)

Print name: FRANK CAMPAGNA

== == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for [†]eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital	Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue			
Add the following:			
 Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 			
 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval 			
 Number of partly paid ordinary securities that became fully paid in that 12 month period 			
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
Subtract the number of fully paid ordinary securities cancelled during that 12 month period			
"A"			
Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
Multiply "A" by 0.15			

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"		
Step 4: Subtract "C" from ["A" x "B"] to calculate under rule 7.1	nte remaining placement capacity	
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which calculated	ch the placement capacity is
"A"	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount of placement already been used	capacity under rule 7.1A that has
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A